{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T23:06:42Z","timestamp":1779577602713,"version":"3.53.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejso.2026.111807","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:30:30Z","timestamp":1776285030000},"page":"111807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adding pembrolizumab to standard neoadjuvant chemoradiotherapy is not associated with increased postoperative complications after esophagectomy in ESCC: a retrospective analysis from a prospective database"],"prefix":"10.1016","volume":"52","author":[{"given":"Lei","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xiang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4197-8887","authenticated-orcid":false,"given":"Shengguang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejso.2026.111807_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.ejso.2026.111807_bib2","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/cam4.3647","article-title":"Esophageal cancer: trends in incidence and mortality in China from 2005 to 2015","volume":"10","author":"He","year":"2021","journal-title":"Cancer Med"},{"issue":"10447","key":"10.1016\/j.ejso.2026.111807_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","article-title":"Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial","volume":"404","author":"Kato","year":"2024","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.ejso.2026.111807_bib4","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.111807_bib5","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","article-title":"Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries","volume":"6","author":"Zeng","year":"2018","journal-title":"Lancet Global Health"},{"issue":"35","key":"10.1016\/j.ejso.2026.111807_bib6","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10459","key":"10.1016\/j.ejso.2026.111807_bib7","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ejso.2026.111807_bib8","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.111807_bib9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejca.2020.11.039","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)","volume":"144","author":"Li","year":"2020","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejso.2026.111807_bib10","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1158\/1078-0432.CCR-20-4443","article-title":"Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT)","volume":"27","author":"van den Ende","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ejso.2026.111807_bib11","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1016\/j.ejso.2026.111807_bib12","article-title":"Tislelizumab combined with chemotherapy or radiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (TINES): a randomized, open, phase II study","volume":"42","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111807_bib13","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1186\/s12885-025-14682-z","article-title":"Neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a clinical retrospective study","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2026.111807_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.ejso.2026.111807_bib15","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/SLA.0000000000002132","article-title":"The Comprehensive Complication Index (CCI\u00ae): added value and clinical perspectives 3 years \"Down the Line\"","volume":"265","author":"Clavien","year":"2017","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.ejso.2026.111807_bib16","first-page":"403","article-title":"Comparison of the Clavien-Dindo and Comprehensive Complication Index systems for grading of surgical complications after colorectal resections","volume":"122","author":"Smeyers","year":"2021","journal-title":"Acta Chir Belg"},{"issue":"2","key":"10.1016\/j.ejso.2026.111807_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/ijgc-2022-003998","article-title":"Clinical validation and comparison of the Comprehensive Complication Index and Clavien-Dindo classification in predicting post-operative outcomes after cytoreductive surgery in advanced ovarian cancer","volume":"33","author":"Kengsakul","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2026.111807_bib18","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/annonc\/mdw010","article-title":"A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction","volume":"27","author":"Klevebro","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111807_bib19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12885-023-10687-8","article-title":"Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.ejso.2026.111807_bib20","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.ejso.2026.111807_bib21","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-Year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111807_bib22","volume":"12","author":"Shang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejso.2026.111807_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102118","article-title":"A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)","volume":"62","author":"Chen","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ejso.2026.111807_bib24","article-title":"Evaluation of neoadjuvant immunotherapy and traditional neoadjuvant therapy for resectable esophageal cancer: a systematic review and single-arm and network meta-analysis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ejso.2026.111807_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/SLA.0000000000002611","article-title":"Benchmarking complications associated with esophagectomy","volume":"269","author":"Low","year":"2019","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.ejso.2026.111807_bib26","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1097\/JS9.0000000000000487","article-title":"Additional neoadjuvant immunotherapy does not increase the risk of anastomotic leakage after esophagectomy for esophageal squamous cell carcinoma: a multicenter retrospective cohort study","volume":"109","author":"Hong","year":"2023","journal-title":"Int J Surg"},{"issue":"2","key":"10.1016\/j.ejso.2026.111807_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doad057","article-title":"The effect of aging on short- and long-term results after esophagectomy: an international multicenter retrospective analysis","volume":"37","author":"Mengardo","year":"2024","journal-title":"Dis Esophagus"},{"issue":"2","key":"10.1016\/j.ejso.2026.111807_bib28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11605-014-2686-y","article-title":"Impact of body mass index on surgical outcomes after esophagectomy for patients with esophageal squamous cell carcinoma","volume":"19","author":"Hasegawa","year":"2014","journal-title":"J Gastrointest Surg"},{"issue":"12","key":"10.1016\/j.ejso.2026.111807_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123868","article-title":"Performance of comprehensive complication index and clavien-dindo complication scoring system in liver surgery for hepatocellular carcinoma","volume":"12","author":"Giani","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ejso.2026.111807_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12070-019-01718-7","article-title":"Use of clavien-dindo classification system in assessing head and neck surgery complications","volume":"72","author":"Vallur","year":"2019","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"issue":"3","key":"10.1016\/j.ejso.2026.111807_bib31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1470-2045(20)30685-9","article-title":"Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial","volume":"22","author":"Xu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2026.111807_bib32","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1245\/s10434-016-5291-3","article-title":"Using the comprehensive complication index to assess the impact of neoadjuvant chemoradiotherapy on complication severity after esophagectomy for cancer","volume":"23","author":"Nederlof","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.111807_bib33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s10388-022-00911-y","article-title":"Comprehensive complication index as a prognostic factor in minimally invasive esophagectomy for esophageal squamous cell carcinoma","volume":"19","author":"Kudo","year":"2022","journal-title":"Esophagus"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326004269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326004269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T22:59:47Z","timestamp":1779577187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326004269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0748798326004269"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111807","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adding pembrolizumab to standard neoadjuvant chemoradiotherapy is not associated with increased postoperative complications after esophagectomy in ESCC: a retrospective analysis from a prospective database","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111807"}}